PULSE › Topics › Retatrutide
Retatrutide
3 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
6 sources
6 articles
v 4
3d ago
↑ Rising
Business
🔮 fades
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
3 sources
3 articles
v 1
11h ago
◼ Archived
Business
🔮 fades
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
5 sources
5 articles
v 3
4d ago